Skip to content






*The second dose of vaccine/placebo will be administered 1 to 2 months after the first dose.
Month 2 (Visit 3), Month 7 (Visit 4) and Month 13 (Visit 5) occurred within 1, 6 and 12 months of the second vaccination, respectively. RZV, recombinant zoster vaccine; YOA, years of age.



Humoral response was measured at Mo 2, Mo 7 and Mo 13, which occurred within 1, 6 and 12 months of the second vaccination, respectively.
Mo, month; RZV, recombinant zoster vaccine; VRR, vaccine response rate; YOA, years of age.
Reproduced from Vink P et al. 2020 under the terms of a Creative Commons CC-BY licence (


column-graph-depicting-the-vaccine-response-rate-for-cell-mediated-immune-responses-in-renal-transplant-patients-stratified-by-age,-specifically-18-to-49-years-of-age-and-those-aged-50-years-or-older.-The-vaccine-response-rate-for-cell-mediated-immune-response-in-the-vaccine-group-at-month-2-was-approximately-80-percent-and-60-percent-in-18-to-49-years-of-age-cohort-and-the-50-years-and-older-cohort-respectively.-at-each-time-point,-cell-mediated-immune-responses-appeared-to be-higher-in-the-18-to-49-years-of-age-cohort-compared-to-the-50-years-and-older-cohort.-cell-mediated-immune-vaccine-response-rates-in-the-placebo-group-remained-near-the-pre-vaccination-level-

Cell-mediated immune response was measured at Mo 2 and Mo 13, which occurred within 1 and 12 months of the second vaccination, respectively.
CMI, cell-mediated immunity; Mo, month; RZV, recombinant zoster vaccine; VRR, vaccine response rate; YOA, years of age
Reproduced from Vink P et al. 2020 under the terms of a Creative Commons CC-BY licence (

RZVワクチン接種後の液性免疫応答率は、2回目接種1ヶ月後で80.2%、13ヶ月後で66.7%であった。各時点で、液性免疫応答および細胞性免疫応答は、18-49 歳の若年層で 50 歳以上の層よりも高かった。
年齢に関係なく、腎移植後 4~18ヶ月にワクチン投与された場合、gEに対する液性および細胞性免疫応答が誘導された20

column-graph-depicting-the-local and general reactions in-renal-transplant patients-who-received-either-the-recombinant-zoster-vaccine-or-placebo.-in-patients-who-received-the-recombinant-zoster-vaccine,-the-most-frequently-reported-local-adverse-reaction-was-injection-site-pain;-fatigue,-myalgia-and-headache-were-the-most-frequently-reported-general-reactions-

Grade 3 pain defined as significant pain at rest and preventing normal activity; grade 3 redness and swelling defined as surface diameter >100 mm. Fever defined as ≥37.5°C; Fever was not graded in this study. Fever >39.0°C presented as grade 3.
For all others, grade 3 AEs defined as preventing normal activity.

AE, adverse event; GI, gastrointestinal symptoms (nausea, vomiting, diarrhoea and/or abdominal pain); RZV, recombinant zoster vaccine.

Graphs reproduced from Vink P et al. 2020 under the terms of a Creative Commons CC-BY licence (, with additional data from NCT02058589.



AE, adverse event; pIMD, potential immune-mediated disease; RZV, recombinant zoster vaccine; SAE, serious adverse event.
The graph has been independently created by GSK from Vink P, et al. Clin Infect Dis. 2020;70(2):181–190.

RZV 群とプラセボ群との間で、AE、SAE(死亡に至るSAE含む)、免疫の関与が疑われる疾患(pIMD)、生検で証明された拒絶反応、移植臓器の機能変化について、明らかな差は認められませんでした20


AE, adverse event; ART, anti-retroviral therapy; ATP, according to protocol; BCL, B-cell lymphoma; CLL, chronic lymphocytic leukaemia; CMI, cell-mediated immunity; gE, glycoprotein E; GI, gastrointestinal; GMC, geometric mean concentration; HIV, human immunodeficiency virus; IQR, interquartile range; LL, lower limit; Mo, month; mTVC, modified total vaccinated cohort; pIMD, potential immune-mediated disease; PHN, post-herpetic neuralgia; Pre, pre-vaccination; Q, quartile; RZV, recombinat zoster vaccine; SAE, serious adverse event; TVC, total vaccinated cohort; UL, upper limit; VE, vaccine efficacy; VRR, vaccine response rate; YOA, years of age


  1. Chen SY, et al. Infection. 2014;42(2):325–334
  2. Zhang D, et al. Adv Ther. 2017;34(7):1610–1621.
  3. Sahoo F, et al. Biol Blood Marrow Transplant. 2017;23(3):505–511.
  4. Winston DJ, et al. Lancet. 2018;391(10135):2116–2127
  5. Bastidas A, et al. JAMA. 2019;322(2):123–133
  6. Habel LA, et al. Cancer Epidemiol Biomarkers Prev. 2013;22(1):82–90
  7. Dagnew AF, et al. Lancet Infect Dis. 2019;19(9):988–1000
  8. Koo S, et al. Transpl Infect Dis. 2014;16(1):17–25
  9. Pergam SA, et al. Transpl Infect Dis. 2011;13(1):15–23
  10. Arness T, et al. Transpl Infect Dis. 2008;10(4):260–268
  11. Mao J, et al. Medicine (Baltimore). 2017;96(48):e8746
  12. Tseng HF, et al. Clin Infect Dis. 2014;59(7):913–919
  13. Blank LJ, et al. J Acquir Immune Defic Syndr. 2012;61(2):203–207
  14. Chakravarty EF. Rheum Dis Clin North Am. 2017;43(1):111–121
  15. Veetil BM, et al. Arthritis Care Res (Hoboken). 2013;65(6):854–861
  16. Khan N, et al. Clin Gastroenterol Hepatol. 2018;16(12):1919–1927
  17. Johnson BH, et al. BMC Infect Dis. 2015;15:502
  18. Dagnew AF, et al. Hum Vaccin Immunother. 2021;17(11):4132–4143
  19. Berkowitz EM, et al. J Infect Dis. 2015;211(8):1279–1287
  20. Vink P, et al. Clin Infect Dis. 2020;70(2):181–190
  21. Vink P, et al. Cancer. 2019;125(8):1301–1312
  22. de la Serna J, et al. Efficacy and Safety of an Adjuvanted Herpes Zoster Subunit Vaccine in Autologous Hematopoietic Stem Cell Transplant Recipients 18 Years of Age or Older: First Results of the Phase 3 Randomized, Placebo-Controlled ZOE-HSCT Clinical Trial. Presented at BMT Tandem Meeting; 25th February 2018; Salt Lake City, UT, USA.
  23. NCT01610414. Available at: (accessed May 2023).
  24. Zoster-002 Clinical Study Report 115523. Available at: (accessed May 2023).
  25. Zoster-039 Clinical Study Report 116428. Available at: (accessed May 2023)
  26. NCT01798056. Available at: (accessed May 2023).
  27. Zoster-028 Clinical Study Report 116427. Available at: (accessed May 2023).
  28. Vink P. Immunogenicity and Safety of a Candidate Subunit Adjuvanted Herpes Zoster Vaccine in Adults with Solid Tumors Vaccinated Before or During Immunosuppressive Chemotherapy Treatment: A Phase II/III, Randomized Clinical Trial. Poster #1349. Presented at IDWeek; 4–8 October, 2017; San Diego, CA, USA.
  29. NCT02058589. Available at: (accessed May 2023).
  30. Vink P, et al. Open Forum Infect Dis. 2018;5(suppl 1):S744–S745
  31. Zoster-041 Clinical Study Report 116886. Available at: (accessed May 2023).
  32. Zoster-015 Clinical Study Report 112673. Available at: (accessed May 2023).

NX-JP-SGX-WCNT-230014 | December 2023